

# Policy for Resubmission of Grant Proposals

## **Purpose**

To establish clear guidelines for the resubmission of grant proposals that advanced to the full proposal stage of a previous RFA cycle, but were not selected for funding.

### Scope

Applies to all grant proposals submitted to CureSearch for funding consideration through the Young Investigator, Acceleration Initiative, and Catapult award mechanisms.

#### **Definitions**

IAC Industry Advisory Council

LOI Letter of Intent

SAC Scientific Advisory Council
SRC Scientific Review Committee
RFA Request for Applications

#### **Procedures**

## Eligibility for Resubmission:

Applicants may resubmit a proposal for funding consideration once following an initial review.

## Letter of Intent (LOI) Submission:

Applicants must first submit an LOI following all guidelines outlined in the relevant RFA. Applicants must mark the LOI as a resubmission in the Proposal Central LOI site. The SRC will review LOIs based on established criteria specific to the RFA and selected high-scoring applicants will be invited to submit a full proposal.

#### Full Proposal Submission:

Applicants invited to resubmit a full proposal following review of their LOI must mark the proposal as a resubmission in the Proposal Central full application site. Applicants must provide a cover letter to accompany the resubmitted protocol that includes:

- 1) Reviewer comments from the original review cycle.
- 2) A detailed explanation of how each comment has been addressed in the resubmitted proposal, with specific changes made in response to the feedback.

### Full Proposal Application Review

Resubmitted proposals will compete with new proposals for funding. The SRC will thoroughly review and score full proposals based on established criteria specific to the RFA. For Acceleration Initiative and Catapult awards, the IAC will also review applications for commercialization potential and marketability. The SAC will review SRC and IAC



critiques (if applicable) and further prioritize applications for funding based on scientific rationale and alignment with CureSearch funding priorities.